PacBio management to participate in investor conferences.
ByAinvest
Wednesday, Aug 6, 2025 9:07 am ET1min read
MS--
PacBio, headquartered in Menlo Park, California, specializes in designing, developing, and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems [3]. The company's products and technologies, including HiFi long-read sequencing, address a broad range of research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [3]. PacBio's solutions are provided for Research Use Only and are not intended for use in diagnostic procedures [3].
The Canaccord Genuity 45th Annual Growth Conference will take place on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, Massachusetts. The Morgan Stanley 23rd Annual Global Healthcare Conference will be held on Wednesday, September 10, 2025, at 12:20 PM ET in New York, New York [1]. Investors can access the live webcasts of these events through PacBio's investor relations website, with replays available for at least 30 days following each event [1].
References:
1. [1] https://www.stocktitan.net/news/PACB/pac-bio-to-present-at-upcoming-investor-2horjqbhc0sh.html
2. [2] https://www.globenewswire.com/news-release/2025/08/06/3128361/16261/en/PacBio-to-Present-at-Upcoming-Investor-Conferences.html
3. [3] https://www.pacb.com
PACB--
PacBio, a developer of high-quality sequencing solutions, announced that management will participate in upcoming investor conferences. The events include the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. Live webcasts of the events can be accessed on the company's investors page. A replay will be available for at least 30 days following the event.
PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in two upcoming investor conferences. The events include the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025 [1]. Management will present at both conferences, with live webcasts available for investors to access on the company's investors page. Replays of the webcasts will be available for at least 30 days following each event [2].PacBio, headquartered in Menlo Park, California, specializes in designing, developing, and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems [3]. The company's products and technologies, including HiFi long-read sequencing, address a broad range of research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [3]. PacBio's solutions are provided for Research Use Only and are not intended for use in diagnostic procedures [3].
The Canaccord Genuity 45th Annual Growth Conference will take place on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, Massachusetts. The Morgan Stanley 23rd Annual Global Healthcare Conference will be held on Wednesday, September 10, 2025, at 12:20 PM ET in New York, New York [1]. Investors can access the live webcasts of these events through PacBio's investor relations website, with replays available for at least 30 days following each event [1].
References:
1. [1] https://www.stocktitan.net/news/PACB/pac-bio-to-present-at-upcoming-investor-2horjqbhc0sh.html
2. [2] https://www.globenewswire.com/news-release/2025/08/06/3128361/16261/en/PacBio-to-Present-at-Upcoming-Investor-Conferences.html
3. [3] https://www.pacb.com
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet